首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Pyrrolopyrimidines: novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models.
【24h】

Pyrrolopyrimidines: novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models.

机译:吡咯并嘧啶:在脑损伤和局部缺血模型中具有神经保护活性的新型可穿透脑的抗氧化剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A novel group of antioxidant compounds, the pyrrolopyrimidines, has been discovered recently. Many of these possess significantly improved oral bioavailability (56-70% in rats), increased efficacy and potency in protecting cultured neurons against iron-induced lipid peroxidative injury and as much as a 5-fold increase in brain uptake compared with the 21-aminosteroid antioxidant compound, tirilazad mesylate (U-74006F), described earlier. They appear to quench lipid peroxidation reactions by electron-donating and/or radical-trapping mechanisms. Several compounds in the series, such as U-101033E and U-104067F, demonstrate greater ability than tirilazad to protect the hippocampal CA1 region in the gerbil transient (5-min) forebrain ischemia model. Delaying treatment until 4 hr after the ischemic insult still results in significant CA1 neuronal protection. U-101033E is still effective in salvaging a portion of the CA1 neuronal population when the ischemic duration is extended to 10 min. In addition, U-101033E has been found to be protective in the context of focal cerebral ischemia, reducing infarct size in the mouse permanent middle cerebral artery occlusion model, in contrast to tirilazad which is minimally effective. These results suggest that antioxidant compounds with improved brain parenchymal penetration are better able to limit certain types of ischemic brain damage than those which are localized in the cerebral microvasculature. However, the activity of U-101033E in improving early post-traumatic recovery in mice subjected to severe concussive head injury is similar to that of tirilazad. Last, the oral bioavailability of many pyrrolopyrimidines suggests that they may be useful for certain chronic neurodegenerative disorders in which lipid peroxidation plays a role.
机译:最近发现了一组新的抗氧化剂化合物,吡咯并嘧啶。这些中的许多具有显着改善的口服生物利用度(在大鼠中为56-70%),在保护培养的神经元免受铁诱导的脂质过氧化损伤方面提高了功效和效力,并且与21-氨基类固醇相比,其大脑摄取增加了5倍抗氧化剂化合物甲磺酸替拉扎德(U-74006F),如前所述。它们似乎通过给电子和/或自由基捕获机制来猝灭脂质过氧化反应。该系列中的几种化合物(例如U-101033E和U-104067F)在沙土鼠短暂(5分钟)前脑缺血模型中具有比tirilazad保护海马CA1区更大的能力。将治疗延迟至缺血性损伤后4个小时仍可导致明显的CA1神经元保护。当缺血持续时间延长至10分钟时,U-101033E仍可有效挽救部分CA1神经元群体。此外,已发现U-101033E在局灶性脑缺血的情况下具有保护作用,与起效最低的tirilazad相比,可减少小鼠永久性大脑中动脉闭塞模型的梗塞面积。这些结果表明,与位于脑微脉管系统中的那些化合物相比,具有改善的脑实质渗透性的抗氧化剂化合物能够更好地限制某些类型的缺血性脑损伤。但是,U-101033E在改善遭受严重脑震荡的小鼠的创伤后早期恢复中的活性与tirilazad相似。最后,许多吡咯并嘧啶的口服生物利用度表明,它们可能对某些脂质过氧化起作用的慢性神经退行性疾病有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号